Integrated BioPharma, Inc. (INBP)
OTCMKTS · Delayed Price · Currency is USD
0.1890
+0.0040 (2.16%)
At close: Oct 9, 2026
Integrated BioPharma Cash Flow Statement
Financials in millions USD. Fiscal year is July - June.
Millions USD. Fiscal year is Jul - Jun.
Operating Activities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Net Income | -2.84 | 0.81 | 0.11 | -0.03 | 3.84 |
Depreciation & Amortization | 1.39 | 1.27 | 1.22 | 1.15 | 0.83 |
Loss (Gain) From Sale of Assets | -0.01 | 0 | 0 | -0 | -0.02 |
Asset Writedown & Restructuring Costs | 0.03 | 0.03 | - | - | - |
Loss (Gain) From Sale of Investments | - | - | - | 0.01 | 0.06 |
Stock-Based Compensation | 0.19 | 0.19 | 0.25 | 0.32 | 0.37 |
Provision & Write-off of Bad Debts | - | 0.02 | -0.04 | 0 | - |
Other Operating Activities | 0.27 | 1.25 | 0.14 | 0.08 | -1.5 |
Change in Accounts Receivable | 2.1 | -0.78 | -0.12 | 0.37 | 0.88 |
Change in Inventory | 0.22 | 1.88 | -0.98 | 0.79 | 0.64 |
Change in Accounts Payable | 0.93 | -0.21 | 0.24 | -0.92 | -0.22 |
Change in Other Net Operating Assets | -1.03 | -2.39 | 0.12 | -0.55 | -0.78 |
Operating Cash Flow | 1.24 | 2.07 | 0.94 | 1.23 | 4.09 |
Operating Cash Flow Growth | -39.90% | 118.98% | -23.46% | -69.88% | 34.13% |
Investing Activities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Capital Expenditures | -0.35 | -0.19 | -0.55 | -0.12 | -0.49 |
Sale of Property, Plant & Equipment | 0.01 | - | - | 0 | 0.02 |
Investment in Securities | - | - | - | 0 | - |
Other Investing Activities | - | -0.01 | - | - | - |
Investing Cash Flow | -0.34 | -0.21 | -0.55 | -0.11 | -0.47 |
Financing Activities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Short-Term Debt Repaid | - | - | - | -0.1 | -2.07 |
Long-Term Debt Repaid | -0.05 | -0.01 | -0.04 | -0.04 | -1.47 |
Total Debt Repaid | -0.05 | -0.01 | -0.04 | -0.14 | -3.54 |
Net Debt Issued (Repaid) | -0.05 | -0.01 | -0.04 | -0.14 | -3.54 |
Issuance of Common Stock | - | 0.09 | 0.01 | - | 0.03 |
Financing Cash Flow | -0.05 | 0.08 | -0.03 | -0.14 | -3.51 |
Net Cash Flow
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Net Cash Flow | 0.86 | 1.94 | 0.36 | 0.99 | 0.12 |
Free Cash Flow
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Free Cash Flow | 0.9 | 1.87 | 0.39 | 1.12 | 3.61 |
Free Cash Flow Growth | -52.24% | 380.51% | -65.05% | -69.04% | 30.85% |
Free Cash Flow Margin | 2.04% | 3.45% | 0.78% | 2.20% | 6.41% |
Free Cash Flow Per Share | 0.03 | 0.06 | 0.01 | 0.04 | 0.11 |
Levered Free Cash Flow | 2.8 | 1.94 | 1.18 | 1.93 | 3.3 |
Unlevered Free Cash Flow | 2.81 | 1.97 | 1.21 | 1.94 | 3.38 |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Cash Interest Paid | 0.01 | 0.05 | 0.04 | 0.04 | 0.11 |
Cash Income Tax Paid | - | 0.08 | 0.04 | - | 0.47 |
Change in Working Capital | 2.21 | -1.5 | -0.74 | -0.3 | 0.51 |